Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039
The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions
Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy's for a consideration of Rs. 275 crore
Marksans' OTC Famotidine Tablets USP are acid reducers
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
The cash consideration for the above acquisition will be Euro 26 million.
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Subscribe To Our Newsletter & Stay Updated
